Abbott Labs: Too Cheap to Ignore?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Looking for a cheap stock with name-brand power and a strong, diversified portfolio of products? At first glance, you couldn't do much better than Abbott Labs (NYSE: ABT  ) . The company's stock has jumped more than 5.4% year-to-date since its spinoff of former pharmaceutical business AbbVie (NYSE: ABBV  ) , yet it's still trading at a price-to-earnings ratio of just over 9.8.

Impressed? Buyer beware: This is a textbook example of why the P/E ratio, one of the fundamental numbers for valuing stocks, isn't always an investor's best friend. For all its strengths and potential, Abbott's not as cheap as it looks.

As cheap as it looks?
Comparing Abbott's P/E to other major diversified health care firms would make many investors think it an extraordinarily cheap stock. Johnson & Johnson (NYSE: JNJ  ) by comparison sports a much higher P/E of 21.3, while Merck's (NYSE: MRK  ) is even higher, at 22.7. Abbott's stock has outperformed Merck over the past year, and its 23% growth compares well with J&J's. But is Abbott so cheap after all?

This is a case where it's important to read the fine print. Price-to-earnings ratios involve earnings over the trailing 12 months. Guess what Abbott still had over its last reported 12 months? If you guessed AbbVie -- its pharmaceuticals division and now-independent company that made up the biggest single division by sales and a huge chunk of earnings last year -- you're right.

AbbVie reported net earnings for the past year of $5.2 billion – earnings actually earned by Abbott, which saw full-year 2012 earnings of around $6 billion in all. Take away that $5.2 billion and Abbott's P/E grows substantially. To get a better idea of the new Abbott's real valuation, take a look at its forward P/E, based upon analyst projections of future earnings over the next fiscal year. Abbott's forward P/E of 15 makes it a good deal more expensive than Johnson & Johnson's forward P/E of 13.8 or Merck's considerably smaller ratio of 11.5.

Cheap? Perhaps not after you consider Abbott's downsizing. But that doesn't mean this is a stock you should avoid; on the contrary, Abbott has plenty of growth opportunities ahead despite shedding its blockbuster-fueled branded pharmaceuticals business.

Reasons for faith
The branded pharmaceuticals business is notable for its high margins and boom-or-bust risks. Losing that business doesn't lend itself to cheap P/E valuations for Abbott's future, with divisions such as nutritionals and generic drugs fueling tomorrow's revenue. Still, this company didn't make a shortsighted move by spinning off AbbVie.

On the contrary, Abbott refocused into a leaner, more stable firm that will keep on rewarding investors for some time to come. Shedding its pharmaceutical business freed Abbott from the patent-cliff-related headaches affecting rivals such as Merck, which has struggled to recapture revenue lost from blockbuster drug Singulair's patent expiration. While spinoff AbbVie will have to deal with the loss of massive blockbuster drug Humira's patent protection in the near future, Abbott can look forward to a stable, if slower-growing, future.

Nonetheless, if Abbott interests you, don't judge the stock by its P/E valuation. There are plenty of reasons to have faith in this company's future, from its emerging market growth in areas such as nutritionals to its dominant position in the drug-eluting stent market. Buying it just because it looks cheap at first glance, however, is a move that will leave investors disappointed.

Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.

Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 08, 2013, at 10:44 AM, PEStudent wrote:

    Thanks for a very informative article, which helps me as an Abbott Labs DRIP owner since 1991 and now an Abbott and Abbvie owner.

    I'd like to see similar analysis on Abbvie. If Abbvie helps lower Abbott's P/E more than it should be, then doesn't Abbott raise Abbvie's P/E more than it should be? And Abbvie, up from it's $35 initial spinoff price in January, is $41.30 right now at a P/E of only 12.38.

    Abbvie is set to lose it's majority-income maker when Humira's patent expires in 2016. To invest in Abbvie long term, you have to be betting that there will be profits from the more than 20 drugs in mid to late-stage clinical programs.

    Abbott - moving more into hospital equipment, etc. seems a good, stable stock and Abbvie is definitely a more-risky play.

    I will note than in January, when I had to sell some stock in order to pay cash for a new car (I don't keep a lot of cash in the bank), I sold some of my Abbott, not my Abbvie. If one of the two is going to shine, I think it will be Abbvie: it has to 2016 to before it Humira's patent expires and, with our corrupt Congress, it will be able to extend an effective patent for several years. That should help keep the company firing on all cylinders until the pipeline or some bought-out foreign company's pharmaceuticals come online.

  • Report this Comment On April 09, 2013, at 11:14 AM, stockdoc00 wrote:

    Both are great stocks but I still feel in the long run, ABT has much more growth potential than ABBV and I added to my ABT position after the spinoff but continue to hold tight on my ABBV shares.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2350912, ~/Articles/ArticleHandler.aspx, 9/25/2016 1:27:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
ABT $42.19 Down -0.03 -0.07%
Abbott Laboratorie… CAPS Rating: *****
JNJ $118.81 Down -0.65 -0.54%
Johnson and Johnso… CAPS Rating: *****
MRK $62.96 Down -0.06 -0.10%
Merck and Co. CAPS Rating: ****